ELLAS Life Sciences Group has reported significant findings from their Phase 1 clinical trial of SLS009, a CDK9 inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML).
Molecular Templates highlighted the promising results of their monotherapy drug candidate, MT-6402, particularly in patients with head and neck cancer.
The Phase 1b clinical trial for a novel antidepressant, VLS-01, developed by atai Life Sciences, has commenced with the dosing of the first participant.
Indaptus Therapeutics has reported encouraging outcomes from the second group of participants in its Phase 1 clinical trial for a drug candidate called Decoy20.
A new formulation of an HIV drug, cabotegravir ultra long-acting (CAB-ULA), has demonstrated the potential for dosing intervals of at least four months.
Revelation Biosciences has initiated a Phase 1 clinical trial for its proprietary compound Gemini, which is designed to leverage trained immunity for disease prevention and treatment.